Aspirin chemoprevention combined with colonoscopy screening is not cost-effective for the general population.
However, the cost-effectiveness of aspirin in individuals with prior adenoma resection has not been evaluated.
Dr DuPont and colleagues from Texas, USA evaluated the cost-effectiveness of aspirin chemoprevention alone.
|Aspirin chemoprevention alone showed a gain of 0.009 years|
|Alimentary Pharmacology & Therapeutics|
The team also assessed the cost-effectiveness of aspirin chemoprevention in combination with colonoscopy surveillance in patients with prior adenoma resection.
The research team constructed a model of the natural history of individuals with a history of endoscopic polypectomy.
The team compared 4 strategies including no intervention, routine colonoscopy surveillance, aspirin chemoprevention alone, and aspirin therapy combined with colonoscopy.
Compared with no intervention, all other strategies were more costly but were associated with gains in years of life saved.
The team found that aspirin chemoprevention alone was associated with a gain of 0.009 years.
Routine colonoscopic surveillance and combination strategy were associated with further gains in years of life saved.
Compared with no intervention, the team noted that incremental cost-effectiveness ratio of routine colonoscopy surveillance was $78,226 per year of life saved.
The incremental cost-effectiveness ratio of combination aspirin and colonoscopy was $60,942 per year of life saved.
Dr DuPont's team concluded, "Aspirin chemoprevention combined with colonoscopic surveillance in post-polypectomy patients may be considered a cost-effective strategy."